Critical Reviews in Oncology / Hematology
Volume 77, Issue 1 , Pages 20-29 , January 2011

Genomic Grade Index: An important tool for assessing breast cancer tumor grade and prognosis

  • Otto Metzger Filho

      Affiliations

    • Institut Jules Bordet, 121 Boulevard de Waterloo, B-1000 Brussels, Belgium
    • Corresponding Author InformationCorresponding author. Tel.: +32 02541 3145; fax: +32 02541 3477.
    • ,
  • Michail Ignatiadis

      Affiliations

    • Medical Oncology Department, Translational Research Unit, Institut Jules Bordet, 121 Boulevard de Waterloo, B-1000 Brussels, Belgium
    • ,
  • Christos Sotiriou

      Affiliations

    • Institut Jules Bordet, 121 Boulevard de Waterloo, B-1000 Brussels, Belgium

,Accepted 15 January 2010.

References 

  1. Greenough RB. Varying degrees of malignancy in cancer of the breast. J Cancer Res. 1925;9:453–462
  2. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;20:3628–3636
  3. Patey DH, Scarff RW. The position of histology in the prognosis of carcinoma of the breast. Lancet. 1928;i:801–804
  4. Bloom HJ. Prognosis in carcinoma of the breast. Br J Cancer. 1950;4:259–288
  5. Bloom HJ. Further studies on prognosis of breast carcinoma. Br J Cancer. 1950;4:347–367
  6. Elston CW. Pathological aspects of the UK Breast Screening Project with special reference to minimal and ‘borderline’ lesions. Aust N Z J Surg. 1984;54:201–204
  7. Black MM, Barclay TH, Hankey BF. Prognosis in breast cancer utilizing histologic characteristics of the primary tumor. Cancer. 1975;36:2048–2055
  8. Hartveit F. Prognostic typing in breast cancer. Br Med J. 1971;4:253–257
  9. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957;11:359–377
  10. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403–410
  11. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:966–978
  12. Haybittle JL, Blamey RW, Elston CW, et al. A prognostic index in primary breast cancer. Br J Cancer. 1982;45:361–366
  13. Genestie C, Zafrani B, Asselain B, et al. Comparison of the prognostic value of Scarff–Bloom–Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: major importance of the mitotic count as a component of both grading systems. Anticancer Res. 1998;18:571–576
  14. Kollias J, Murphy CA, Elston CW, et al. The prognosis of small primary breast cancers. Eur J Cancer. 1999;35:908–912
  15. Reed W, Hannisdal E, Boehler PJ, et al. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14–30 years. Cancer. 2000;88:804–813
  16. Le Doussal V, Tubiana-Hulin M, Friedman S, et al. Prognostic value of histologic grade nuclear components of Scarff–Bloom–Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer. 1989;64:1914–1921
  17. Longacre TA, Ennis M, Quenneville LA, et al. Interobserver agreement and reproducibility in classification of invasive breast carcinoma: an NCI breast cancer family registry study. Mod Pathol. 2006;19:195–207
  18. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–2826
  19. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006;98:262–272
  20. Quackenbush J. Microarray analysis and tumor classification. N Engl J Med. 2006;354:2463–2472
  21. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 2003;100:10393–10398
  22. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–10874
  23. van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009
  24. Wirapati P, Sotiriou C, Kunkel S, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008;10:R65
  25. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–752
  26. Eisen MB, Spellman PT, Brown PO, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA. 1998;95:14863–14868
  27. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418–8423
  28. Calza S, Hall P, Auer G, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res. 2006;8:R34
  29. Ihemelandu CU, Leffall LD, Dewitty RL, et al. Molecular breast cancer subtypes in premenopausal African-American women, tumor biologic factors and clinical outcome. Ann Surg Oncol. 2007;14:2994–3003
  30. Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006;7:p96
  31. Yu K, Lee CH, Tan PH, et al. Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations. Clin Cancer Res. 2004;10:5508–5517
  32. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360:790–800
  33. Sauter G, Lee J, Bartlett JM, et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009;27:1323–1333
  34. Cheang MC, Chia SK, Voduc D, et al. Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer. J Natl Cancer Inst. 2009;101:736–750
  35. Oyama T, Ishikawa Y, Hayashi M, et al. The effects of fixation, processing and evaluation criteria on immunohistochemical detection of hormone receptors in breast cancer. Breast Cancer. 2007;14:182–188
  36. Loi S, Haibe-Kains B, Desmedt C, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol. 2007;25:1239–1246
  37. Liedtke C, Hatzis C, Symmans WF, et al. Genomic Grade Index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol. 2009;
  38. Guarneri V, Broglio K, Kau SW, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. 2006;24:1037–1044
  39. Feldman LD, Hortobagyi GN, Buzdar AU, et al. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res. 1986;46:2578–2581
  40. Fisher ER, Wang J, Bryant J, et al. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer. 2002;95:681–695
  41. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25:4414–4422
  42. Desmedt C, Haibe-Kains B, Wirapati P, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008;14:5158–5165
  43. van’t Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–536
  44. Buyse M, Loi S, van’t Veer L, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst. 2006;98:1183–1192
  45. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726–3734
  46. Albain K, Barlow W, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer. Breast Cancer Res Treat. 2007;106:
  47. Haibe-Kains B, Desmedt C, Piette F, et al. Comparison of prognostic gene expression signatures for breast cancer. BMC Genomics. 2008;9:394
  48. Desmedt C, Piette F, Loi S, et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res. 2007;13:3207–3214
  49. The NCCN Clinical Practice Guidelines in Oncology™ Breast Cancer (Version 1.2010). © 2009 National Comprehensive Cancer Network, Inc. Available at: NCCN.org [cited].
  50. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287–5312
  51. Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20:1319–1329
  52. Cardoso F, Van’t Veer L, Rutgers E, et al. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol. 2008;26:729–735
  53. Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol. 2008;26:721–728
  54. Hornberger J, Cosler LE, Lyman GH. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care. 2005;11:313–324

PII: S1040-8428(10)00012-0

doi: 10.1016/j.critrevonc.2010.01.011

Critical Reviews in Oncology / Hematology
Volume 77, Issue 1 , Pages 20-29 , January 2011

Article Tools

* Image Usage & Resolution